This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. This is a Phase I dose escalation trial to evaluate the safety and immunogenicity of a highly attenuated live Salmonella expressing HIV-Gag. Healthy adult HIV-negative volunteers will be admitted as inpatients, given oral doses of the vaccine, and be monitored for 14 days as inpatients followed by 6 weeks as outpatients. The major endpoint is to gain safety and immunogenicity data about Salmonella as a live attenuated bacterial vector. Immune responses to Salmonella and HIV gag will also be studied.
Showing the most recent 10 out of 945 publications